InterShunt key facts
- Developer of a proprietary catheter system designed to provide relief to people suffering from heart failure.
- InterShunt’s last known valuation is $140.0M.
- It has raised $31.4M; the latest was Later Stage VC ($23.4M) in Sep 2024.
- Notable investors include MedTech Innovator, gBETA, IAG Capital Partners, BioGenerator Ventures, Accelerate Venture Partners — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch InterShunt: the Monday email on marks, rounds and moves
InterShunt funding rounds
No funding rounds for InterShunt are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
InterShunt valuation
InterShunt's last known valuation is $140 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
InterShunt investors
8 investors are on record for InterShunt, including MedTech Innovator, gBETA, IAG Capital Partners and BioGenerator Ventures.
About InterShunt
Developer of a proprietary catheter system designed to provide relief to people suffering from heart failure. The company's system is an interatrial shunting device that requires no implant and no energy for the capturing and excision of tissue from the interatrial septum, enabling doctors to reduce left atrial pressure in heart failure patients.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2015
- Employees
- 10
- Website
- intershunt.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
InterShunt’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.